Consun Pharmaceutical (Inner Mongolia) Co., Ltd.

The main purpose of the study is to use the empagliflozin tablets (specification: 10 mg, trade name: Otangjing®) certified by Boeheringer Ingelheim International GmbH as the reference preparation and the empagliflozin tablets (specification: 10 mg) developed by Kangchen Pharmaceutical (Inner Mongolia) Co., Ltd. as the test preparation, and to evaluate the bioequivalence of the two preparations in the fasting and postprandial state through a single-center, randomized, open, single-dose, two-cycle, double-crossover clinical study. Secondary purpose of the study: To observe the safety of the test preparation and the reference preparation in healthy adult subjects in China.

To preliminarily evaluate the efficacy and safety of Huangqi Powder Micropills in the treatment of diabetic kidney disease (Qi deficiency syndrome), explore the advantageous dose of Huangqi Powder Micropills in the treatment of diabetic kidney disease, and provide support for the next step of clinical research design.

Through Phase IIb clinical trials, the safety and effectiveness of Tongluo Jiunao Injection in treating the acute phase of cerebral infarction and meridian disorders in stroke (wind-fire disturbance, blood stasis blocking the meridians) were further evaluated.